Evidence map›Paper›PMID 35006715›Full record

ArticleACS applied bio materials2021

Photo-cross-linked Gelatin Glycidyl Methacrylate/N-Vinylpyrrolidone Copolymeric Hydrogel with Tunable Mechanical Properties for Ocular Tissue Engineering Applications.

Sina Sharifi, Hannah Sharifi, Ali Akbari, Darrell Koza, Claes H Dohlman, Eleftherios I Paschalis, James Chodosh

Open access · greenAbstract read
In one paragraph

Article in ACS applied bio materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Bioinspired Tissue Transparency: Achieving Sclera-to-Cornea Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sina SharifiDisruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0003-2681-2907
Hannah SharifiDisruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Ali AkbariSolid Tumor Research Center, Research Institute for Cellular and Molecular Medicine, Urmia University of Medical Sciences, 57147, Urmia, Iran.ORCID 0000-0001-6027-292X
Darrell KozaDepartment of Physical Sciences, Eastern Connecticut State University, Willimantic, Connecticut 06226, United States.
Claes H DohlmanDisruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Eleftherios I PaschalisDisruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.
James ChodoshDisruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0002-7463-1599
Massachusetts Eye and Ear Infirmary · USEastern Connecticut State University · USUrmia University · IR

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Tobias Elze · 1985 to 2026
$25.5M
Generation of suturable artificial cornea from the integration of exfoliated graphene with gelatin glycidyl methacrylateK99EY030553 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI SHARIFI, SINA · 2020 to 2022
$242k
NEI NIH HHS K99 EY030553NEI NIH HHS P30 EY003790
6 · The paper itself

Abstract

Corneal transplantation is currently the primary treatment for corneal blindness. However, severe global scarcity of donor corneas is driving the scientific community to find novel solutions. One potential solution is to replace the damaged tissue with a biocompatible artificial cornea. Here, gelatin glycidyl methacrylate (GM) and

Indexed as

GelatinTissue EngineeringEpoxy CompoundsHumansHydrogelsMethacrylatesPyrrolidinonesTissue ScaffoldsEpoxy CompoundsGelatinglycidyl methacrylateHydrogelsMethacrylatesN-vinyl-2-pyrrolidinonePyrrolidinonesbiocompatiblecopolymercorneal substitutegelatin glycidyl methacrylatehydrogelN-vinylpyrrolidone

Identifiers

PMID35006715
PMCPMC8855968
OpenAlexW3201341167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.